Gap Junction Potentiation of Endothelial Function With Rotigaptide
Recruitment status was: Recruiting
|First Submitted Date ICMJE||May 13, 2009|
|First Posted Date ICMJE||May 14, 2009|
|Last Update Posted Date||May 14, 2009|
|Start Date ICMJE||March 2009|
|Estimated Primary Completion Date||March 2010 (Final data collection date for primary outcome measure)|
|Current Primary Outcome Measures ICMJE
||Change in Substance P and ACh vasodilatation caused by potentiation of gap junction communication with Rotigaptide in the context of endothelial dysfunction [ Time Frame: Vasodilatation will be assesed before and after ischaemic periods ]|
|Original Primary Outcome Measures ICMJE||Same as current|
|Change History||No Changes Posted|
|Current Secondary Outcome Measures ICMJE
||Change in Substance P induced t PA release caused by potentiation of gap junction communication with Rotigaptide in the context of endothelial dysfunction [ Time Frame: Venous blood samles will be taken at regular time points throught the protocol ]|
|Original Secondary Outcome Measures ICMJE||Same as current|
|Current Other Outcome Measures ICMJE||Not Provided|
|Original Other Outcome Measures ICMJE||Not Provided|
|Brief Title ICMJE||Gap Junction Potentiation of Endothelial Function With Rotigaptide|
|Official Title ICMJE||Gap Junction Potentiation of Endothelial Function With Rotigaptide in the Human Forearm Arterial Circulation - Effects of Ischaemia Induced Endothelial Dysfunction|
Hypothesis - Rotigaptide will improve endothelial function in the context of endothelial dysfunction.
The lining of blood vessels (endothelium) can react to hormones in the blood stream causing the blood vessel muscle to relax (vasodilatation) and allow more blood to flow. The nitric oxide and prostacyclin pathways are well documented in this process. However, evidence points to the existence of a third powerful relaxant called endothelium derived hyperpolarising factor (EDHF) but its identity and mechanism of action have proved elusive. As well as causing blood vessels to relax and more blood to flow, EDHF may be involved in the endothelium signaling, triggering release of a specialised clot dissolving factor called tissue plasminogen activator (t PA). t PA is important to ensure small clots, which are constantly being formed in the circulation, are rapidly dissolved and do not grow large enough to cause heart attacks and strokes.
Evidence points towards the requirement for 'gap junctions' in the mediation of EDHF responses. Gap junctions are specialised pores which allow small molecules and charge to pass between cells. They are found between endothelial cells and the underlying muscle of the blood vessel. A drug called Rotigaptide has been developed to cause gap junctions to open. It has been safely administered in healthy volunteers and is now in a Phase II drug trial. By opening gap junctions the investigators hypothesise that it could increase EDHF mediated activity and vasodilatation. It represents a useful tool with which to examine the role of gap junctions in EDHF activity in vivo.
Previously the investigators have demonstrated that rotigaptide does not contribute to endothelial function in healthy volunteers. The investigators now wish to examine the effect of rotigaptide in conditions of endothelial dysfunction. By limiting the blood flow to the arm for 20mins the ability of the blood vessel to vasodilate is impaired. By administering an intra−arterial rotigaptide infusion the investigators want to assess any functional preservation.
BACKGROUND The endothelium plays a pivotal role in the control of vascular tone and is responsible for the local release of profibrinolytic factors. Nitric oxide (NO), the original endothelium-derived relaxing factor, and prostacyclin (PGI2) have now been well characterised. The elucidation of their roles in vascular physiology and pathophysiology has been fundamental to recent advances in the treatment and prevention of many cardiovascular diseases. Whilst these factors are of major importance, evidence points to the existence of a third powerful vasodilator called endothelium-derived hyperpolarising factor (EDHF).
Endothelium-dependent vasodilatation -
After blockade of both NO and PGI2, a substantial degree of endothelium-dependent vasodilatation is still observed and is attributed to EDHF. Despite almost two decades of research and debate, the exact nature of EDHF and its mechanism of action remain unclear. Consistently, EDHF's role as a vasodilator is most prominent in the smaller resistance arteries that are responsible for the control of systemic blood pressure and local organ perfusion. As well as its involvement in physiological processes, alterations in EDHF activity may contribute to the vascular effects of the myriad of conditions either caused by, or resulting in, endothelial dysfunction. However, the lack of understanding of EDHF has precluded its direct manipulation as a specific therapeutic target.
Endogenous fibrinolysis -
In addition to its function in the control of vascular tone, there is evidence to suggest that EDHF may be responsible for the endothelial release of the pro-fibrinolytic factor, tissue-type plasminogen activator (t-PA).
Thrombus formation and dissolution is a continuous process in the vasculature and is regulated by dynamic interactions between pro-coagulant and pro-fibrinolytic factors. Endogenous fibrinolysis is determined by the relative balance between the acute local release of t-PA from the endothelium and its subsequent inhibition by plasma plasminogen activator inhibitor type 1 (PAI-1). In the presence of an imbalance in the fibrinolytic system, subclinical microthrombi on the surface of atherosclerotic plaques may propagate and ultimately lead to arterial occlusion and tissue infarction.
The mechanisms via which t-PA release is mediated are incompletely understood. Bradykinin, an endogenous endothelium-dependent vasodilator, causes the endothelial release of t-PA. However, Brown et al have demonstrated that inhibition of prostacyclin and nitric oxide synthesis does not diminish bradykinin mediated endothelial t-PA release in the human forearm. Therefore, they suggest that EDHF is responsible for the endothelial release of t-PA but, to date, this hypothesis has not been adequately addressed.
Gap Junctions -
Gap junctions are found at points of cell-cell contact where they form an aqueous pore through which small hydrophilic molecules and ionic charge may pass. Each gap junction comprises two hemichannels, or connexons that are composed of six connexin (Cx) subunits. Although each connexon may be composed of a mix of connexin subtypes, Cx37, Cx40 and Cx43 are particularly associated with mammalian endothelium and vascular smooth muscle.
The case for a pivotal role of gap junctions in the EDHF phenomenon has strengthened. Gap junction plaques are most abundant in small resistance arteries and their distribution is proportional to the magnitude of the EDHF-mediated response. These topographical data have been extrapolated to argue for a direct link between gap junctions and EDHF. Furthermore, murine knockout models provide direct evidence for a role of gap junctions and specific connexins in the control of vascular tone.
Potentiation of Communication via Gap Junctions -
Rotigaptide (ZP-123) is a novel hexapeptide (Ac-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly-NH2), originally developed as an antiarrythmic agent it has now been safely administered to healthy humans as a six day continuous infusion of up to 20 mg (0.30 mmol) per day and is now in Phase II clinical trials. It has been shown to promote electrical coupling between ventricular myocytes by increasing gap junction conductance potentially via alterations in the phosphorylation status of Cx43 and it increases the number of gap junctions in the ischaemic myocardium It potentiates gap junction-mediated dye transfer via Cx43 expressing HeLa cells but not via Cx26 or Cx32 but its effects on electrical conduction and dye transfer via Cx37 and Cx40, the other major vascular connexins, have yet to be assessed. However, we have recently shown that Cx43 is required for the mediation of EDHF vasodilatation of human subcutaneous resistance vessels.
We have recently demonstrated that rotigaptide does not enhance endothelium-dependent or independent forearm arterial vasodilatation in healthy volunteers. However there may be a role for potentiating gap junctions under some circumstances. In animal models of myocardial infarction those treated with rotigaptide had significantly reduced infarction sizes. Endothelial dysfunction is central to the pathophysiology of diabetes and is responsible for the vascular complications associated with this condition. In animal models of diabetes reduced expression of connexins has been demonstrated with blunted response to EDHF, suggesting a link between endothelial dysfunction and gap junctions.
Endothelial dysfunction can be mimicked in vivo with brief periods of ischaemia, resulting in a reduced response to endothelium-dependant vasodilators. In the forearm arterial circulation, we will test the hypothesis that rotigaptide-induced enhancement of communication via gap junctions attenuates ischaemic endothelial dysfunction.
|Study Type ICMJE||Interventional|
|Study Phase||Not Provided|
|Study Design ICMJE||Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
|Publications *||Not Provided|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Unknown status|
|Estimated Enrollment ICMJE||24|
|Completion Date||Not Provided|
|Estimated Primary Completion Date||March 2010 (Final data collection date for primary outcome measure)|
|Eligibility Criteria ICMJE||
|Ages||18 Years to 64 Years (Adult)|
|Accepts Healthy Volunteers||Yes|
|Contacts ICMJE||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries ICMJE||United Kingdom|
|Removed Location Countries|
|NCT Number ICMJE||NCT00901563|
|Other Study ID Numbers ICMJE||CZB/4/520/b|
|Has Data Monitoring Committee||No|
|U.S. FDA-regulated Product||Not Provided|
|IPD Sharing Statement||Not Provided|
|Responsible Party||Dr Gareth Barnes, Research Fellow, University of Edinburgh|
|Study Sponsor ICMJE||University of Edinburgh|
|PRS Account||University of Edinburgh|
|Verification Date||May 2009|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP